PL2176231T3 - Podstawione pochodne indazolu aktywne jako inhibitory kinazy - Google Patents

Podstawione pochodne indazolu aktywne jako inhibitory kinazy

Info

Publication number
PL2176231T3
PL2176231T3 PL08785975T PL08785975T PL2176231T3 PL 2176231 T3 PL2176231 T3 PL 2176231T3 PL 08785975 T PL08785975 T PL 08785975T PL 08785975 T PL08785975 T PL 08785975T PL 2176231 T3 PL2176231 T3 PL 2176231T3
Authority
PL
Poland
Prior art keywords
kinase inhibitors
indazole derivatives
substituted indazole
derivatives active
active
Prior art date
Application number
PL08785975T
Other languages
English (en)
Inventor
Borgia Andrea Lombardi
Maria Menichincheri
Paolo Orsini
Achille Panzeri
Ettore Perrone
Ermes Vanotti
Marcella Nesi
Chiara Marchionni
Original Assignee
Nerviano Medical Sciences S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39764856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2176231(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nerviano Medical Sciences S.R.L. filed Critical Nerviano Medical Sciences S.R.L.
Publication of PL2176231T3 publication Critical patent/PL2176231T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL08785975T 2007-07-20 2008-07-08 Podstawione pochodne indazolu aktywne jako inhibitory kinazy PL2176231T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07112881 2007-07-20
EP08785975.7A EP2176231B1 (en) 2007-07-20 2008-07-08 Substituted indazole derivatives active as kinase inhibitors

Publications (1)

Publication Number Publication Date
PL2176231T3 true PL2176231T3 (pl) 2017-04-28

Family

ID=39764856

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08785975T PL2176231T3 (pl) 2007-07-20 2008-07-08 Podstawione pochodne indazolu aktywne jako inhibitory kinazy

Country Status (29)

Country Link
US (11) US8299057B2 (pl)
EP (1) EP2176231B1 (pl)
JP (1) JP5506674B2 (pl)
KR (2) KR101636312B1 (pl)
CN (2) CN101754956B (pl)
AR (1) AR067599A1 (pl)
AU (1) AU2008280283B2 (pl)
BR (1) BRPI0814628B1 (pl)
CA (1) CA2693901C (pl)
CL (1) CL2008002129A1 (pl)
DK (1) DK2176231T3 (pl)
EA (1) EA018503B1 (pl)
ES (1) ES2605230T3 (pl)
FI (1) FIC20200051I1 (pl)
FR (1) FR20C1064I2 (pl)
HU (2) HUE030929T2 (pl)
IL (1) IL203292A (pl)
NL (1) NL301090I2 (pl)
NO (2) NO2020042I1 (pl)
NZ (1) NZ583450A (pl)
PH (1) PH12013501594A1 (pl)
PL (1) PL2176231T3 (pl)
PT (1) PT2176231T (pl)
SG (1) SG183049A1 (pl)
SI (1) SI2176231T1 (pl)
TW (1) TWI421073B (pl)
UA (1) UA99141C2 (pl)
WO (1) WO2009013126A1 (pl)
ZA (1) ZA201001086B (pl)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299057B2 (en) * 2007-07-20 2012-10-30 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
ES2552733T3 (es) * 2007-11-16 2015-12-01 Rigel Pharmaceuticals, Inc. Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos
RS53350B (sr) 2008-09-22 2014-10-31 Array Biopharma, Inc. Supstituisana jedinjenja imidazo[1,2-b]piridazina kao inhibitori trk kinaze
PT2725028T (pt) 2008-10-22 2016-08-31 Array Biopharma Inc Compostos de pirazolo[1,5-]pirimidina substituídos como intermediários na síntese de inibidores de cinase trk
MX346801B (es) 2009-03-13 2017-03-31 Agios Pharmaceuticals Inc Métodos y composiciones para trastornos relacionados con la proliferación celular.
JP5756457B2 (ja) 2009-04-06 2015-07-29 アジオス ファーマシューティカルズ， インコーポレイテッド ピルビン酸キナーゼｍ２調節剤、治療組成物および関連する使用方法
WO2010143664A1 (ja) 2009-06-10 2010-12-16 中外製薬株式会社 ４環性化合物
EP2448581B1 (en) 2009-06-29 2016-12-07 Agios Pharmaceuticals, Inc. Therapeutic compositions and related methods of use
SG177434A1 (en) 2009-06-29 2012-02-28 Agios Pharmaceuticals Inc Therapeutic compounds and compositions
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
CA2793836C (en) 2009-10-21 2020-03-24 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
WO2011072174A1 (en) * 2009-12-09 2011-06-16 Agios Pharmaceuticals, Inc. Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
AU2011229542A1 (en) * 2010-03-16 2012-11-08 Merck Patent Gmbh Morpholinylquinazolines
HUE044025T2 (hu) 2010-05-20 2019-09-30 Array Biopharma Inc Makrociklusos vegyületek mint TRK-kináz inhibitorok
TWI476188B (zh) 2010-05-27 2015-03-11 Ube Industries 新穎吲唑衍生物或其鹽及其製造中間體、以及使用其之抗氧化劑
WO2012018668A1 (en) * 2010-08-05 2012-02-09 Amgen Inc. Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase
CA2808210C (en) 2010-08-20 2019-10-01 Chugai Seiyaku Kabushiki Kaisha Tetracyclic compounds having alk inhibitory activity and compositions thereof
WO2012083246A1 (en) 2010-12-17 2012-06-21 Agios Pharmaceuticals, Inc. Novel n- (4- (azetidine - 1 - carbonyl) phenyl) - (hetero - ) arylsulfonamide derivatives as pyruvate kinase m2 (pmk2) modulators
MX336022B (es) 2010-12-21 2016-01-06 Agios Pharmaceuticals Inc Activadores de pkm2 bicíclicos.
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
FR2970967B1 (fr) 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
PT2704721T (pt) 2011-05-03 2018-06-14 Agios Pharmaceuticals Inc Ativadores da piruvato-cinase para utilização em terapia
JP6396210B2 (ja) * 2011-05-12 2018-09-26 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤として活性な置換インダゾール誘導体
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
UA117451C2 (uk) 2012-01-06 2018-08-10 Аджиос Фармасьютікалз, Інк. Терапевтично активні сполуки і способи їх застосування
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
NZ716487A (en) * 2012-05-23 2017-01-27 Nerviano Medical Sciences Srl Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
EP2689779A1 (en) 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk
CA3077553C (en) 2012-09-25 2022-08-02 Chugai Seiyaku Kabushiki Kaisha Ret inhibitor
WO2014062511A1 (en) 2012-10-15 2014-04-24 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
US9617242B2 (en) 2012-12-19 2017-04-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015006591A1 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
JP6441323B2 (ja) * 2013-09-25 2018-12-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 化合物およびメソゲン媒体
TWI672141B (zh) * 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
UA121211C2 (uk) 2014-03-14 2020-04-27 Аджіос Фармасьютикалз, Інк. Фармацевтична композиція, що містить тверду дисперсію, та спосіб лікування гострої мієлогенної/мієлоїдної лейкемії (гмл)
WO2015143652A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
JP6873698B2 (ja) 2014-04-25 2021-05-19 中外製薬株式会社 ４環性化合物の新規結晶
MY200583A (en) 2014-04-25 2024-01-04 Chugai Pharmaceutical Co Ltd Formulation containing a large amount of tetracyclic compound
KR101731624B1 (ko) * 2014-07-01 2017-05-04 광주과학기술원 세포 리프로그래밍 유도용 조성물
TWI803187B (zh) 2014-08-08 2023-05-21 日商中外製藥股份有限公司 包含４環性化合物的非晶質體之固體分散體及製劑
FI3699181T3 (fi) 2014-11-16 2023-03-28 Array Biopharma Inc Kiteinen muoto (s)-n-(5-((r)-2-(2,5-diluorifenyyli)-pyrrolidin-1-yyli)-pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidivetyysulfaatista
KR102595599B1 (ko) * 2014-12-02 2023-11-02 이그니타, 인코포레이티드 신경모세포종의 치료를 위한 병용
US20170356918A1 (en) * 2014-12-03 2017-12-14 Ignyta, Inc. Multiplexed immunohistochemistry assays for diagnosis and treatment of cancer
WO2016096709A1 (en) 2014-12-16 2016-06-23 Eudendron S.R.L. Heterocyclic derivatives modulating activity of certain protein kinases
BR112017013982A2 (pt) 2015-01-16 2018-01-02 Chugai Seiyaku Kabushiki Kaisha fármaco de combinação
EP3303382A4 (en) * 2015-05-29 2018-12-19 Ignyta, Inc. Compositions and methods for treating patients with rtk mutant cells
MX2017015461A (es) 2015-06-01 2018-08-15 Loxo Oncology Inc Métodos para diagnosticar y tratar el cáncer.
SI3307271T1 (sl) 2015-06-11 2023-11-30 Agios Pharmaceuticals, Inc. Postopki za uporabo aktivatorjev piruvat kinaze
PL3322706T3 (pl) 2015-07-16 2021-07-19 Array Biopharma, Inc. Podstawione związki pirazolo[1,5-a]pirydynowe jako inhibitory kinazy ret
DK3362066T3 (da) 2015-10-15 2021-11-22 Les Laboratoires Servier Sas Kombinationsterapi til behandling af maligniteter
MD3362065T2 (ro) 2015-10-15 2024-08-31 Servier Lab Terapie combinată care conține ivosidenib, citarabină și daunorubicina sau idarubicina pentru tratarea leucemiei acute mielogene
EP3368039A1 (en) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Point mutations in trk inhibitor-resistant cancer and methods relating to the same
EP3389645A4 (en) 2015-12-18 2019-12-18 Ignyta, Inc. COMBINATIONS FOR TREATING CANCER
CA3019661A1 (en) 2016-04-04 2017-10-12 Loxo Oncology, Inc. Methods of treating pediatric cancers
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
RS65987B1 (sr) 2016-04-04 2024-10-31 Loxo Oncology Inc Tečne formulacije (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirolidin-1-il)-pirazolo[1,5-]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
EP3800189B1 (en) 2016-05-18 2023-06-28 Loxo Oncology, Inc. Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
CN109153669B (zh) 2016-05-24 2021-12-24 内尔维阿诺医学科学有限公司 苯甲酰胺类化合物的新晶型
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
EP3626709A1 (en) * 2017-06-26 2020-03-25 Shenzhen Targetrx, Inc. Indazole compound for use in inhibiting kinase activity, composition and application thereof
WO2019018570A1 (en) 2017-07-19 2019-01-24 Ignyta, Inc. PHARMACEUTICAL COMPOSITIONS CONTAINING ENTRECTINIB
US10180422B1 (en) 2017-08-22 2019-01-15 Scripps Health Methods of treating a neuroendocrine tumor
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
JP7311498B2 (ja) * 2017-10-17 2023-07-19 イグナイタ インコーポレイテッド 薬学的組成物および剤形
KR102179406B1 (ko) 2017-10-17 2020-11-16 한국화학연구원 신규한 인다졸 유도체 및 이의 용도
US20190247398A1 (en) 2017-10-26 2019-08-15 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
SG11202004384YA (en) 2017-11-17 2020-06-29 Univ Illinois Cancer therapy by degrading dual mek signaling
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
WO2019191659A1 (en) 2018-03-29 2019-10-03 Loxo Oncology, Inc. Treatment of trk-associated cancers
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CN117281803A (zh) 2018-07-31 2023-12-26 罗索肿瘤学公司 喷雾干燥的分散体和制剂
US11969472B2 (en) 2018-08-22 2024-04-30 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
IL280984B2 (en) 2018-08-22 2025-02-01 Cullgen Shanghai Inc Tropomyosin receptor kinase (TRK) inhibitor compounds and methods of use
PL3848361T3 (pl) 2018-09-04 2025-07-07 Chugai Seiyaku Kabushiki Kaisha Sposób wytwarzania związku tetracyklicznego
WO2020055672A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
CA3114385A1 (en) 2018-10-05 2020-04-09 The Board Of Trustees Of The University Of Illinois Combination therapy for the treatment of uveal melanoma
CN111205227A (zh) * 2018-11-22 2020-05-29 四川大学 3-乙烯基吲唑类衍生物及其制备方法和用途
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
JP2022515197A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド がんを治療するためのｆｇｆｒ阻害剤としての７－（（３，５－ジメトキシフェニル）アミノ）キノキサリン誘導体
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
EP3725777A1 (en) * 2019-04-17 2020-10-21 Rottapharm Biotech S.r.l. Benzo- and pyrido-pyrazoles as protein kinase inhibitors
EP4003309A1 (en) 2019-07-31 2022-06-01 F. Hoffmann-La Roche AG New pharmaceutical formulation
TW202114676A (zh) 2019-08-14 2021-04-16 瑞士商Ｆ 賀夫曼 賀許公司 治療癌症之方法
WO2021084260A1 (en) * 2019-11-01 2021-05-06 Johnson Matthey Public Limited Company Crystalline entrectinib anhydrate and monohydrate forms; crystalline entrectinib thf, nitromethane, isopropyl acetate and methanol solvate forms; processes for preparing a crystalline entrectinib anhydrate form
CN111171009B (zh) * 2020-01-10 2022-07-12 安礼特（上海）医药科技有限公司 恩曲替尼晶型及其制备方法
WO2023205701A1 (en) 2022-04-20 2023-10-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
EP4110772A4 (en) 2020-02-26 2024-04-03 Cullgen (Shanghai), Inc. TROPOMYOSIN-RELATED KINASE RECEPTOR (TRK) DEGRADING COMPOUNDS AND METHODS OF USE
CN113354626B (zh) * 2020-03-04 2025-06-03 罗欣药业(上海)有限公司 恩曲替尼的晶型及其制备方法
WO2021197467A1 (zh) * 2020-04-02 2021-10-07 上海华汇拓医药科技有限公司 多靶点的抗肿瘤化合物及其制备方法和应用
CN113801062B (zh) * 2020-06-15 2023-05-26 沈阳药科大学 3-氨基-5-(3,5-二氟苄基)-1h-吲唑的制备方法
CN116157394A (zh) * 2020-07-15 2023-05-23 艾福姆德尤股份有限公司 用于治疗与sting活性有关的疾病的化合物和组合物
CN114230518A (zh) * 2021-12-13 2022-03-25 海南梵圣生物科技有限公司 一种5-苄基-1h-吲唑-3-胺类化合物的制备方法
WO2023137034A1 (en) * 2022-01-12 2023-07-20 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN115746023B (zh) * 2022-10-27 2024-08-09 复旦大学 一种作为蛋白激酶抑制剂的含吲唑结构的杂环大环化合物及其制备方法
AU2024276994A1 (en) 2023-05-24 2025-10-23 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
TW202502779A (zh) 2023-06-30 2025-01-16 美商金橘生物科技公司 取代的雜芳族胺及其用途
TW202523291A (zh) 2023-11-02 2025-06-16 美商金橘生物科技公司 降解劑及其用途
CN119684214A (zh) * 2024-11-09 2025-03-25 四川大学华西医院 一种3-氨基吲唑类共价化合物的制备及其治疗帕金森应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002353186A1 (en) * 2001-12-19 2003-06-30 Smithkline Beecham P.L.C. (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors
FR2836915B1 (fr) * 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
FR2871158A1 (fr) 2004-06-04 2005-12-09 Aventis Pharma Sa Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
EA017852B1 (ru) * 2006-12-20 2013-03-29 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Производные замещенных индазолов, активные в качестве ингибиторов киназ
US8299057B2 (en) * 2007-07-20 2012-10-30 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
JP5580332B2 (ja) * 2008-12-18 2014-08-27 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤として活性な置換インダゾール誘導体
NZ716487A (en) * 2012-05-23 2017-01-27 Nerviano Medical Sciences Srl Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
KR101776546B1 (ko) * 2013-10-21 2017-09-07 도요타지도샤가부시키가이샤 전지 시스템

Also Published As

Publication number Publication date
SG183049A1 (en) 2012-08-30
AU2008280283B2 (en) 2013-11-07
US9255087B2 (en) 2016-02-09
EA201070167A1 (ru) 2013-07-30
WO2009013126A1 (en) 2009-01-29
US20150065520A1 (en) 2015-03-05
CN103923072A (zh) 2014-07-16
US8299057B2 (en) 2012-10-30
NL301090I1 (nl) 2021-02-03
NZ583450A (en) 2012-05-25
HK1141278A1 (en) 2010-11-05
US9102662B2 (en) 2015-08-11
BRPI0814628B1 (pt) 2022-04-05
US20130018036A1 (en) 2013-01-17
US9029356B2 (en) 2015-05-12
US20150057292A1 (en) 2015-02-26
HUE030929T2 (en) 2017-06-28
NO2025029I1 (no) 2025-06-13
US20150057291A1 (en) 2015-02-26
PH12013501594A1 (en) 2014-05-12
US20190241546A1 (en) 2019-08-08
BRPI0814628A2 (pt) 2017-07-04
AU2008280283A2 (en) 2010-03-18
CA2693901C (en) 2015-12-29
EP2176231A1 (en) 2010-04-21
ES2605230T3 (es) 2017-03-13
ZA201001086B (en) 2011-04-28
CA2693901A1 (en) 2009-01-29
KR20100044859A (ko) 2010-04-30
US20170158677A1 (en) 2017-06-08
EA018503B1 (ru) 2013-08-30
US20220144813A1 (en) 2022-05-12
HK1200162A1 (en) 2015-07-31
NL301090I2 (nl) 2021-06-17
CN103923072B (zh) 2017-05-31
US20160095856A1 (en) 2016-04-07
CN101754956B (zh) 2014-04-23
UA99141C2 (ru) 2012-07-25
KR101636312B1 (ko) 2016-07-05
HUS2000049I1 (hu) 2021-01-28
FR20C1064I2 (fr) 2022-12-02
DK2176231T3 (en) 2016-12-12
CL2008002129A1 (es) 2008-11-21
KR101567763B1 (ko) 2015-11-12
US10081622B2 (en) 2018-09-25
US20100292207A1 (en) 2010-11-18
US9616059B2 (en) 2017-04-11
TWI421073B (zh) 2014-01-01
AR067599A1 (es) 2009-10-14
EP2176231B1 (en) 2016-10-19
NO2020042I1 (no) 2020-11-24
TW200911233A (en) 2009-03-16
PT2176231T (pt) 2016-12-09
FIC20200051I1 (fi) 2020-12-17
IL203292A (en) 2016-06-30
JP2011502959A (ja) 2011-01-27
KR20150058568A (ko) 2015-05-28
SI2176231T1 (sl) 2017-01-31
US20140228351A1 (en) 2014-08-14
FR20C1064I1 (pl) 2021-01-22
AU2008280283A1 (en) 2009-01-29
US8673893B2 (en) 2014-03-18
US9085558B2 (en) 2015-07-21
JP5506674B2 (ja) 2014-05-28
CN101754956A (zh) 2010-06-23
US20200377487A1 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
HUS2000049I1 (hu) Kináz aktivitással rendelkezõ helyettesített imidazol származékok
IL257083A (en) History of phosphorus as kinase inhibitors
IL202318A0 (en) 5-heteroaryl substituted indazoles as kinase inhibitors
IL198247A0 (en) Indazole derivatives useful as l-cpt1 inhibitors
EP2211615A4 (en) PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS
IL189194A0 (en) Substituted benzimidazoles as kinase inhibitors
IL206394A0 (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
IL200047A0 (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
EP2057158B8 (en) Triazole derivatives as kinase inhibitors
EP2173354A4 (en) CHINOXALIN DERIVATIVES AS PI3 KINASE INHIBITORS
ZA201100344B (en) Pyrimidine derivatives as kinase inhibitors
IL218271A0 (en) Heterocyclic compounds as janus kinase inhibitors
IL202034A0 (en) Heterocyclic indazole derivatives
EP2222166A4 (en) INHIBITORS OF HETEROCYCLIC KINASES
IL212842A0 (en) Azaindole derivatives as kinase inhibitors
IL212755A0 (en) Pyrazinopyrazines and derivatives as kinase inhibitors
IL210573A0 (en) Compounds as kinase inhibitors
IL220205A0 (en) Heterocyclic compounds as janus kinase inhibitors
IL205602A0 (en) Pyrazole derivatives as 5-lo inhibitors
ZA200800506B (en) Substituted benzimidazoles as kinase inhibitors
ZA200905235B (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
HK1138596A (en) 5-heteroaryl substituted indazoles as kinase inhibitors
HK1160386A (en) Heterocyclic kinase inhibitors
HK1147909A (en) Heterocyclic kinase inhibitors
HK1150829A (en) Pyrimidine derivatives as kinase inhibitors